Cowen & Co. Sticks to Its Buy Rating for Galapagos NV (GLPG)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Galapagos NV (GLPGResearch Report). The company’s shares closed last Monday at $164.44.

According to, Nadeau is a 4-star analyst with an average return of 3.5% and a 48.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

Currently, the analyst consensus on Galapagos NV is a Strong Buy with an average price target of $196.37.

See today’s analyst top recommended stocks >>

The company has a one-year high of $191.63 and a one-year low of $85.00. Currently, Galapagos NV has an average volume of 112.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.